MX2020007033A - Anticuerpos anti-mct1 y usos de estos. - Google Patents

Anticuerpos anti-mct1 y usos de estos.

Info

Publication number
MX2020007033A
MX2020007033A MX2020007033A MX2020007033A MX2020007033A MX 2020007033 A MX2020007033 A MX 2020007033A MX 2020007033 A MX2020007033 A MX 2020007033A MX 2020007033 A MX2020007033 A MX 2020007033A MX 2020007033 A MX2020007033 A MX 2020007033A
Authority
MX
Mexico
Prior art keywords
mct1
antibodies
antigen
binding fragments
fusion proteins
Prior art date
Application number
MX2020007033A
Other languages
English (en)
Inventor
Yong Wang
Jay Rothstein
Catherine Carriere
Sergey Seregin
Philipe Gobeil
Grace Ki Jeong Lee
Kimberly P Shigenaka
Marcia Gordon
Kim Quon
Raphael D Levy
Jordon K Wang
Ross Chambers
David Francis Tucker
Brad A Screnci
Original Assignee
Immunext Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunext Inc filed Critical Immunext Inc
Publication of MX2020007033A publication Critical patent/MX2020007033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Esta invención generalmente se refiere a anticuerpos y fragmentos de fijación al antígeno de estos, por ejemplo, anticuerpos humanizados, quiméricos y humanos y fragmentos de fijación al antígeno de estos, y proteínas de fusión, composiciones que contienen tales anticuerpos y fragmentos de fijación al antígeno de estos y proteínas de fusión, en donde tales anticuerpos y fragmentos de fijación al antígeno de estos y proteínas de fusión se fijan específicamente a MCT1, por ejemplo, MCT1 humano o no humano y antagonizan, inhiben o bloquean una o más funciones asociadas a MCT1 in vitro y/o in vivo. La invención también se refiere a usos terapéuticos y de diagnóstico de estos anticuerpos anti-MCT1, fragmentos de fijación al antígeno, proteínas de fusión y composiciones que los contienen opcionalmente en donde estos anticuerpos anti-MCT1, fragmentos de fijación al antígeno, proteínas de fusión y composiciones que los contienen se usan en regímenes terapéuticos que además incluyen la administración de otros agentes terapéuticos, por ejemplo, inhibidores mitocondriales y/o biguanidas o inhibidores de MCT1 molécula pequeña.
MX2020007033A 2018-01-05 2019-01-04 Anticuerpos anti-mct1 y usos de estos. MX2020007033A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862614081P 2018-01-05 2018-01-05
US201862703223P 2018-07-25 2018-07-25
US201862717289P 2018-08-10 2018-08-10
US201862719364P 2018-08-17 2018-08-17
PCT/US2019/012415 WO2019136300A2 (en) 2018-01-05 2019-01-04 Anti-mct1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2020007033A true MX2020007033A (es) 2021-02-26

Family

ID=67144294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007033A MX2020007033A (es) 2018-01-05 2019-01-04 Anticuerpos anti-mct1 y usos de estos.

Country Status (12)

Country Link
US (1) US20190263931A1 (es)
EP (1) EP3735427A4 (es)
JP (2) JP2021509822A (es)
KR (1) KR20200106498A (es)
CN (1) CN111757893A (es)
AU (2) AU2019205489A1 (es)
BR (1) BR112020013314A2 (es)
CA (1) CA3087259A1 (es)
IL (1) IL275826A (es)
MX (1) MX2020007033A (es)
TW (1) TWI751398B (es)
WO (1) WO2019136300A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136300A2 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof
WO2021076620A1 (en) 2019-10-15 2021-04-22 Eli Lilly And Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TWI745906B (zh) * 2020-03-27 2021-11-11 國立臺灣大學 烯丙胍聚合物及其製備方法與應用
AU2021246922A1 (en) * 2020-03-30 2022-10-20 Crystal Bioscience Inc. Anti-GIPR antibody and methods of use thereof
US20220062336A1 (en) * 2020-08-31 2022-03-03 The Johns Hopkins University Method for accelerating nerve regeneration
WO2023003907A1 (en) * 2021-07-19 2023-01-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
AU2022347031A1 (en) 2021-09-14 2024-03-14 Immunometabolism Development Company, Llc Human monocarboxylate transporter 1 antibodies and uses thereof
CN114181945B (zh) * 2021-12-17 2023-10-31 中山大学附属第一医院 tRNA m7G修饰、WDR4、METTL1在机体发育的功能和应用
CN117430697A (zh) * 2022-07-21 2024-01-23 佰舟生物科技(苏州)有限公司 抗mct1抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) * 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2004041156A2 (en) * 2002-01-23 2004-05-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health Andhuman Services Method for determining sensitivity to a bacteriophage
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
US7740856B2 (en) * 2005-12-20 2010-06-22 Isu Abxis Co., Ltd. Effect of BST2 on inflammation
US20080206239A1 (en) * 2005-02-03 2008-08-28 Antitope Limited Human Antibodies And Proteins
JP2011511638A (ja) * 2008-02-07 2011-04-14 シェーリング コーポレイション 抗ｔｓｌｐｒ抗体の設計製作
EP2361095B1 (en) * 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to raise albumin and/or lower crp
GB0904214D0 (en) * 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
BR112013012943A2 (pt) * 2010-11-29 2020-08-11 Genentech, Inc método de diagnóstico de uma disfunção neurodegenerativa em um sujeito, método de monitoramento de doença, método de avaliação de predisposição e kit
CN103732259A (zh) * 2011-06-24 2014-04-16 森彻斯有限公司 细胞外靶向药物缀合物
CN106999576B (zh) * 2014-09-08 2021-09-03 国立癌症研究中心 癌细胞特异性抗体、抗癌剂、及癌症的检查方法
GB201418626D0 (en) * 2014-10-20 2014-12-03 Univ London Queen Mary Method
CA2969730A1 (en) * 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
RU2732591C2 (ru) * 2015-09-25 2020-09-21 Дженентек, Инк. Анти-tigit антитела и способы применения
WO2019136300A2 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3735427A4 (en) 2021-09-15
TWI751398B (zh) 2022-01-01
JP2021509822A (ja) 2021-04-08
WO2019136300A2 (en) 2019-07-11
TW201938200A (zh) 2019-10-01
IL275826A (en) 2020-08-31
CA3087259A1 (en) 2019-07-11
WO2019136300A3 (en) 2019-09-26
EP3735427A2 (en) 2020-11-11
JP2022160650A (ja) 2022-10-19
BR112020013314A2 (pt) 2020-12-01
AU2019205489A1 (en) 2020-06-25
US20190263931A1 (en) 2019-08-29
AU2022215229A1 (en) 2022-10-06
KR20200106498A (ko) 2020-09-14
CN111757893A (zh) 2020-10-09

Similar Documents

Publication Publication Date Title
MX2020007033A (es) Anticuerpos anti-mct1 y usos de estos.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12018501554A1 (en) Ror1 antibody compositions and related methods
MY186974A (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201290525A1 (ru) Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
PH12019501319A1 (en) Gremlin-1 crystal structure and inhibitory antibody
PH12021550764A1 (en) Trem2 stabilizing antibodies
EA201390813A1 (ru) Антитела и их применение
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2021015974A (es) Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
PH12019502694A1 (en) Anti-trkb antibodies
EA202091393A1 (ru) Анти-мст1 антитела и их применение
ZA202205813B (en) Trpv1 epitopes and antibodies
MX2022015948A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.